Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000711742 | SCV000842134 | uncertain significance | not provided | 2017-09-18 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001334992 | SCV001528014 | uncertain significance | Charcot-Marie-Tooth disease type 2D | 2018-07-19 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV002233728 | SCV002508427 | likely benign | Charcot-Marie-Tooth disease type 2 | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026810 | SCV003743680 | uncertain significance | not specified | 2021-08-23 | criteria provided, single submitter | clinical testing | The c.2159A>C (p.E720A) alteration is located in exon 17 (coding exon 17) of the GARS gene. This alteration results from a A to C substitution at nucleotide position 2159, causing the glutamic acid (E) at amino acid position 720 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |